News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Kyong Hwa Park

Articles by Kyong Hwa Park

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

ByPedram Razavi,Judith Balmaña,Stephen Luen,Mario Campone,Laura Cortesi,Norikazu Masuda,Kyong Hwa Park,Qingyuan Zhang,Emily Nizialek,Cathy Qi,Karen Cui,Sibylle Loibl,Mark Robson, MD,Filipa Lynce

April 22nd 2025

Latest Updated Articles

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
April 22nd 2025

Trending on CancerNetwork

Blinatumomab Substitution Improves EFS in Pediatric High-Risk B-ALL

Atezolizumab/Chemo Earns FDA Priority Review in Stage III dMMR/MSI-H Colon Cancer

CD20×CD3 Bispecific Antibodies May Be Feasible Bridging Strategy in LBCL

Epcoritamab Yields Superior PFS vs Chemoimmunotherapy in Pretreated LBCL

Talquetamab Plus Daratumumab Improves PFS in Relapsed/Refractory Myeloma